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Abstract
The prognostic value of the metabolic syndrome (MetS) is believed to vary with age. With an elderly population expecting to triple by
2060, it is important to evaluate the validity of MetS in this age group. We examined the association of MetS risk factors with later risk
of type 2 diabetes (T2DM) and cardiovascular disease (CVD) in elderly Caucasian women. We further investigated if stratiﬁcation of
individuals not deﬁned with MetS would add predictive power in deﬁning future disease prevalence of individuals with MetS.
The Prospective Epidemiological Risk Factor Study, a community-based cohort study, followed 3905 Danish women since 2000
(age: 70.1±6.5) with no previous diagnosis of T2DM or CVD, holding all measurements used for MetS deﬁnition; central obesity,
hypertension, hyperlipidemia, and hyperglycemia combined with register-based follow-up information.
Elderly womenwith deﬁnedMetS presented a 6.3-fold increased risk of T2DM (95% conﬁdence interval: [3.74–10.50]) and 1.7-fold
increased risk of CVD (1.44–2.05) compared to women with no MetS risk factors. Subdividing the control group without deﬁned
MetS revealed that both centrally obese controls and controls holding other MetS risk factors also had increased risk of T2DM
(hazard ratio (HR)=2.21 [1.25–3.93] and HR=1.75 [1.04–2.96]) and CVD (HR=1.51 [1.25–1.83] and HR=1.36 [1.15–1.60]) when
compared to controls with no MetS risk factors.
MetS in elderly Caucasian women increased risk of future T2DM and CVD.While not deﬁned with MetS, women holding only some
risk factors for MetS were also at increased risk of T2DM or CVD compared to women with no MetS risk factors.
Abbreviations: ALAT = alanine-aminotransferase, ASAT = aspartate-aminotransferase, BMI = body mass index, C/P ratio =
central/peripheral fat mass ratio, CCBR = Center for Clinical and Basic Research, CVD = cardiovascular disease, DEXA = dual-
energy X-ray absorption, HDL = high-density lipoprotein, IDF = International Diabetes Federation, LDL = low-density lipoprotein,
MetS =metabolic syndrome, PCA = principal component analysis, PERF = Prospective Epidemiological Risk Factor Study, T2DM =
type 2 diabetes mellitus, WBC = white blood cell count.
Keywords: cardiovascular disease, central obesity, elderly, metabolic syndrome, principal component analysis, type 2 diabetes
1. Introduction
The risk of developing type 2 diabetes mellitus (T2DM) and
cardiovascular disease (CVD) increases with age,[1–3] and with a
generally aging population,[4] deﬁnite measures of disease risk in
elderly individuals are necessary. Such strategy would facilitate
timely preventive approaches to reduce the disease burden, as
well as medical costs in an aging population.[5,6] Metabolic
syndrome (MetS) is widely used as a measure to predict the future
risk of T2DM[7,8] and CVD,[9,10] and is founded on ﬁve
metabolic risk markers: central obesity, elevated blood pressure
(BP), dyslipidemia (involving both elevated serum triglycerides
and lowered high-density lipoprotein (HDL) cholesterol), and
elevated fasting glucose.[11,12] Insulin resistance, commonly
believed to be originating from central obesity,[13] is considered
the cornerstone in risk proﬁles describing both T2DM and
CVD,[14] and central obesity has, therefore, with the 2005
International Diabetes Federation (IDF) deﬁnition, been set as the
“entrance criteria” in deﬁning MetS.[15,16] Many studies have
described the association between MetS-based risk factors and
subsequent disease risk; however, most studies are conducted on
middle-aged populations.[10,17–19] There is, a need for studies on
how the current MetS deﬁnition associates to disease risk
speciﬁcally in elderly individuals. This study aimed to investigate
the predictive value of MetS in relation to future risk of T2DM
andCVD in a cohort of elderly Caucasianwomen by applying the
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MetS deﬁnition set by the IDF. This investigation would allow for
an assessment of whether the MetS-based assessment criterion
remains valid in the estimation of future increased risk of T2DM
and CVD development also in an older population.
All present studies within the ﬁeld of MetS report the risk
estimate based on the use of a deﬁnedMetS-group compared to a
reference group not deﬁned with the syndrome. When applying
this dichotomized deﬁnition, it is likely that the reference group
will be heterogeneous and contain individuals who display
variable metabolic proﬁles. Such reference group heterogeneity
would be based on the inclusion of individuals who, while not
meeting the central obesity entrance criterion, might still hold
many otherMetS risk factors, such as hypertension, dyslipidemia
(elevated serum triglycerides and lowered HDL cholesterol), and
hyperglycemia. We here hypothesized that a heterogeneous
metabolic state of the reference group could potentially inﬂuence
the syndrome’s predictive power of disease. To test the inﬂuence
of the reference group, we separated our study control group
into three reference subgroups: centrally obese controls not
deﬁned with MetS, controls with no central obesity but other
MetS risk factors, and controls with no MetS risk factors, and
used principal component analysis (PCA) to visualize the
differences between the MetS group and these reference
subgroups. We further investigated whether the syndrome’s
predictive power of T2DM and CVD would increase when
stratifying the reference group into the three subgroups of
varying risk character. Finally, we also explored the disease risk
proﬁle of T2DM and CVD based solely on cumulating numbers
of MetS risk factors.
2. Methods
2.1. Study population
The Prospective Epidemiological Risk Factor (PERF) study is an
observational, prospective study of elderly Danish women (n=
5855) conducted in 1999 to 2001. The cohort consists of
postmenopausal women who either had previously participated
in clinical randomized placebo-controlled studies or were
screened without being randomized for previous studies at the
Center for Clinical and Basic Research (CCBR) in Copenhagen or
Aalborg, Denmark. Prior studies run at CCBR, which ultimately
lead to the study population in PERF, mainly focused on age-
related diseases such as osteoporosis and osteoarthritis, and both
screen failures and enrolled participants from these studies (n=
8875) were invited and included on equal terms in the PERF
study. The study was carried out in accordance with ICH-GCP
with study protocol approval from the local ethics committees;
The Research Ethics Committee of Copenhagen County and the
Research Ethics Committee of Viborg and North Jutland
Counties, Denmark (approval reference: KA 99070gm). Written
informed consent was obtained from all participants.
Baseline examination comprised a physical examination
including a full-body dual-energy X-ray absorptiometry (DEXA)
scan, blood sampling, and a self-reported questionnaire compil-
ing information on smoking habits, alcohol intake, medical
history, menopause age, physical activity level, and educational
level.
2.2. Deﬁnition of the metabolic syndrome
MetS was deﬁned using a modiﬁed version of the deﬁnition set by
IDF.[15] Waist circumference was not directly measured in PERF,
and therefore the deﬁnition of central obesity was based on a
calculated central/peripheral fat mass ratio (C/P ratio) deter-
mined by DEXA scan. Central fat mass was deﬁned as fat located
at the torso and peripheral fat mass deﬁned as fat located on
arms, legs, and head as determined by DEXA scan. The cohort
was divided into quartiles based on the C/P ratio, and only
subjects in the fourth quartile were deﬁned as centrally obese in
the analysis. All subjects in this quartile had a C/P ratio >1.
The MetS inclusion criteria were deﬁned as a C/P ratio >1 or a
body mass index (BMI) >30kg/m2, and 2 or more of the
following risk factors: increased triglycerides (>1.7mmol/L),
decreased HDL cholesterol (<1.29mmol/L), increased fasting
plasma glucose (>5.6mmol/L), and increased BP (systolic >130
mm Hg or diastolic >85mm Hg or treatment of previously
diagnosed hypertension).
The IDF criteria state that treatment for lipid abnormalities
speciﬁcally targeting HDL cholesterol or triglycerides can be used
as deﬁning the risk factor, rather than the actual serum value
itself. However, as speciﬁed hyperlipidemia treatment was not
part of the questionnaire, we were not able to determine the
speciﬁc lipid-lowering treatments; therefore, only the serum
measurements for these 2 variables were part of the MetS-
deﬁning criteria of dyslipidemia in this study.
2.3. Study endpoints
The study endpoints were a T2DM diagnosis or a CVD event
occurring after participation in PERF. Follow-up information on
T2DM and CVD diagnosis was retrieved from The National
Danish Diabetes Registry and The National Danish Patient
Registry, respectively, using a unique personal identiﬁcation
number for each subject. Classiﬁcation of CVD diagnoses was
completed according to The International Classiﬁcation of
Diseases, 10th revision (version 2016). All diagnoses from
Chapter IX (Diseases of the circulatory system) were included in
the analysis as CVD events.
The dataset used for analysis was deﬁned as subjects with no
missing data for all MetS-deﬁning variables and no T2DM or
CVD diagnosis before PERF (n=3905) as illustrated in Fig. 1.
The maximum follow-up period was 15.1 years (mean follow-
up: 12.7±3.0 years) starting on the day of study enrollment and
ending at either occurrence of an event (register-based diagnosis)
or on December 31, 2014 (registry data retrieval date), whichever
came ﬁrst. Of the entire study population, a total of 762 diabetics
were identiﬁed, whereof 229 subjects were excluded from the
analysis due to diagnosis before study enrollment. CVD diagnosis
was identiﬁed in 3744 subjects, whereof 1313 subjects were
excluded for having a CVD event before study enrollment. Of
these 1313 subjects, 69 were also diagnosed with diabetes before
enrollment, leaving 1217 unique subjects excluded based solely
on CVD event history.
One or several data points for deﬁning MetS were missing for
446 subjects. Sixty-three subjects were underweight (BMI18.5
kg/m2), and thus, the DEXA scan may not be suitable for the
deﬁnition of a relevant C/P ratio in this subgroup. In total, 509
subjects had either missing or inconclusive data points to permit
deﬁnition of MetS. Altogether, 3905 subjects were included for
further analysis.
In addition to the stratiﬁcation based on identiﬁed MetS, data
were analyzed based on a cumulative number ofMetS risk factors
(0–5) in order to investigate the cumulative effect of risk factors.
In this regard, risk factors were dichotomized based on the cutoff
for the MetS criteria.
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2.4. Statistical analysis
Statistical analysis was conducted using MedCalc Statistical
Software v. 14.8.1 (MedCalc Software, Ostend, Belgium),
GraphPad Prism v.6 (GraphPad Software, La Jolla, CA), and
SAS software, Version 9.4 (SAS Institute Inc., Cary, NC). PCA
was performed in R v. 2.15.3 (R Development Core Team,
Vienna, Austria) using the ggbiplot package.
Baseline characteristics of subjects with deﬁned MetS com-
pared to subjects with no risk factors for MetS (Table 1) were
analyzed using Mann–Whitney U test (numerical variables) or
chi-square test (categorical variables).
Multivariate Cox proportional hazards regression model with
age as time scale was used to assess three aspects of theMetS: risk
of developing T2DM and CVD in women deﬁned with MetS
compared to women not deﬁned with the syndrome; risk
associated with the individual MetS risk factors and subsequent
T2DM or CVD (Fig. 2); risk of developing T2DM and CVD in
womenwith deﬁnedMetS, in womenwith central obesity, and up
to one additional MetS risk factor, but not deﬁned with MetS,
and in women with other risk factors for MetS than central
obesity.Women holding no risk factors forMetS were used as the
reference group (Fig. 4A). Categorical variables included in
all multivariate Cox proportional hazard regression models
were current smoking (yes/no), current alcohol consumption (<7
vs≥7 drinks/wk), and physical activity other than walking (<2 vs
≥2 sessions/wk). The Cox proportional hazard regression model
was further used to assess the risk of T2DM and CVD based on
the cumulative number of metabolic risk factors (1–5), where
subjects with no MetS risk factors were used as reference group
(Fig. 4B). Incidence rates were calculated for all groups (Table 2)
as incidence per 1000 person-years.
PCA (Fig. 3A) was computed from C/P ratio, BMI,
triglycerides, HDL cholesterol, fasting glucose, systolic BP,
diastolic BP, smoking status, alcohol consumption, physical
activity, low-density lipoprotein (LDL) cholesterol, total choles-
terol, white blood cell count (WBC), alanine-aminotransferase
Figure 1. Deﬁnition of the study population. CVD = cardiovascular disease, MetS = metabolic syndrome, IDF = International Diabetes Federation, PERF =
Prospective Epidemiological Risk Factor study.
Table 1
Cohort characteristics of elderly women
with and without deﬁned MetS.
MetS by
IDF deﬁnition
(n=818)
Controls not
deﬁned with MetS
(n=3087)
Demographics
Age, y 70.5 (69.8–71.0) 70.3 (69.9–70.6)
Menopause age, y 50.0 (49.0–50.0) 50.0 (50.0–50.0)
Family history of diabetes (%) 8.5 (62) 8.1 (216)
Education
Primary school (%) 71.0 (579) 69.9 (2158)
High school (%) 21.2 (173) 23.0 (709)
University (%) 7.8 (64) 7.1 (220)
Occupation (working, %) 76.0 (621) 74.7 (2303)
Lifestyle
Current smoking (%) 20.8 (170) 22.6 (697)
Alcohol (>7gl/wk, %) 31.2 (255) 34.5 (1059)
Physical activity (≥2 sessions/wk, %) 63.7 (521)
∗
73.5 (2269)
Vitals
Height, cm 160.5 (160.2–161.0) 161.1 (160.8–161.3)
Weight, kg 76.4 (75.4–77.4)
∗
64.6 (64.2–65.1)
BMI, kg/m2 30.0 (29.5–30.3)
∗
24.9 (24.8–25.1)
Systolic blood pressure, mm Hg 155.0 (153.0–156.0)
∗
145.0 (144.0–147.0)
Diastolic blood pressure, mm Hg 85.0 (84.0–86.0)
∗
80.0 (80.0–81.0)
Serum chemistry
Glucose, mmol/L 5.8 (5.8–5.9)
∗
5.2 (5.2–5.2)
Cholesterol, mmol/L 6.4 (6.4–6.5)
∗
6.3 (6.3–6.3)
LDL, mmol/L 4.1 (4.0–4.2)† 3.9 (3.9–3.9)
HDL, mmol/L 1.5 (1.4–1.5)
∗
1.8 (1.8–1.8)
Triglycerides, mmol/L 1.8 (1.7–1.8)
∗
1.1 (1.1–1.2)
White blood cells, 109 cells/L 5.9 (5.8–6.1)
∗
5.4 (5.4–5.5)
ALAT, mmol/L 27.0 (26.0–27.0)
∗
23.0 (23.0–23.0)
ASAT, mmol/L 24.0 (24.0–25.0)
∗
23.0 (23.0–23.0)
Data shown as median value (95% conﬁdence interval) or as percentage (absolute number of cases).
ALAT = alanine-aminotransferase, ASAT = aspartate-aminotransferase, BMI = body mass index,
HDL = high-density lipoprotein, IDF = International Diabetes Federation, LDL = low-density
lipoprotein, MetS = metabolic syndrome.
∗
Signiﬁcantly different from controls (P<0.001).
† Signiﬁcantly different from controls (P=0.007).
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(ALAT), and aspartate-aminotransferase (ASAT). All variables
were assessed for normality, and C/P ratio, BMI, and triglyceride
levels were log-transformed to ensure normality in the data
distribution. Subjects with a WBC serum levels >109 cells/L, or
ALAT or ASAT levels>50mmol/L, were excluded from the PCA
(n=161) to secure a representative presentation of the metabolic
risk factor distribution in the cohort, so that subjects with
extreme WBC, ALAT, and ASAT values would not distort the
analysis. After centering and scaling the data, we obtained the
principal components (PCs) describing the systematic variation in
data across the 15 variables, hence revealing the metabolic
proﬁles in the dataset. The differences between the PC1
components of the four groups were compared using one-way
analysis of variance with 95% conﬁdence limits. Tukey’s test was
applied as post hoc analysis to determine pairwise differences
between groups (Fig. 3B). The relationship between subjects
deﬁned with MetS compared to the 3 non-MetS subgroups was
also analyzed using a Kruskal–Wallis test (Supplemental Digital
Content 1, http://links.lww.com/MD/B253). For P values less
than 0.05, a post hoc test for pairwise comparison of subgroups,
according to Conover,[20] was performed.
3. Results
3.1. Metabolic syndrome in elderly women
Among the elderly women in the PERF cohort, we found that
20.9% were deﬁned having MetS (n=818) (Table 1). The
demographic characteristics, education level, and lifestyle did not
vary among subjects with MetS and controls except for physical
activity level, which was greater in the control group (P<0.001).
Serum LDL and total cholesterol, which are lipid parameters
not used in the MetS deﬁnition, varied signiﬁcantly between the
two groups (P<0.001 and P=0.007, respectively). This was also
the case for WBC and the liver function markers ALAT and
ASAT (P<0.001 for all three variables).
We found a 3.6-fold increased risk of developing T2DM
(hazard ratio (HR)=3.63, 95% conﬁdence interval: [2.93–4.48])
Figure 2. Risk associated with the 5 metabolic risk factors used to deﬁne the metabolic syndrome showed central obesity to be the only risk factor contributing to
increased risk of both T2DM and CVD outcome. Multivariate Cox regression analysis for the risk of developing T2DM and CVD based on individual metabolic risk
factors; central obesity, high blood pressure, elevated fasting glucose, decreased HDL cholesterol, and increased triglyceride levels. Values were adjusted for age,
smoking, alcohol consumption, and physical activity. CVD = cardiovascular disease, T2DM = type 2 diabetes mellitus. Data represent hazard ratio with 95%
conﬁdence interval.
Table 2
Incidence rates of T2DM and CVD within elderly women in the PERF cohort
stratiﬁed based on metabolic deﬁnitions or based on number of risk factors.
Type 2 diabetes CVD
Groups
Person-years
at risk
T2DM
cases
Incidence per
1000 person-years
Lower
95% CI
Upper
95% CI
Person-years
at risk
CVD
cases
Incidence per
1000 person-years
Lower
95% CI
Upper
95% CI
MetS by IDF deﬁnition 8993.4 164 18.2 15.7 21.3 7292.5 487 66.8 61.1 73.0
Central obesity
but no MetS
6923.7 44 6.4 4.7 8.5 5361.6 316 58.9 52.8 65.8
Risk factors for MetS
but no central obesity
25,504.5 127 5.0 4.2 5.9 19,875.5 1093 55.0 51.8 58.4
Controls
not deﬁned with MetS
5636.6 16 2.8 1.7 4.6 4632.2 168 36.3 31.2 42.2
Type 2 diabetes CVD
Number of
risk factors
Person-years
at risk
T2DM
cases
Incidence per
1000 person-years
Lower
95% CI
Upper
95% CI
Person-years
at risk
CVD
cases
Incidence per
1000 person-years
Lower
95% CI
Upper
95% CI
5 662.3 24 36.2 24.3 54.1 520.4 50 96.1 72.8 126.8
4 2963.8 62 20.9 16.3 26.8 2387.5 163 68.3 58.6 79.6
3 7332.5 99 13.5 11.1 16.4 6011.3 364 60.6 54.6 67.1
2 13,001.0 90 6.9 5.6 8.5 10,040.7 601 59.9 55.3 64.8
1 17,461.9 60 3.4 2.7 4.4 13,569.6 718 52.9 49.2 56.9
0 5636.6 16 2.8 1.7 4.6 4632.2 168 36.3 31.2 42.2
CI = conﬁdence interval, CVD = cardiovascular disease, IDF = International Diabetes Federation, MetS = metabolic syndrome, T2DM = type 2 diabetes mellitus.
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and a 1.3-fold increased risk of a CVD event (HR=1.29
[1.16–1.43]) after 12.7±3.0 years of follow-up for subjects with
MetS compared to controls without deﬁned MetS. Given the
strong effects of MetS on disease risk, we further investigated the
relationship between the individual MetS risk factors and
subsequent T2DM or CVD events (Fig. 2).
Central obesity was the only MetS risk factor contributing to
increased risk of both outcomes with a 2-fold increased risk of
T2DM (HR=1.98 [1.57–2.48]) and a 1.5-fold increased risk of a
CVD event (HR=1.48 [1.30–1.68]) (Fig. 2). Elevated fasting
glucose was only related to the development of T2DM (HR=
3.38 [2.71–4.22]) and did not contribute to an increased risk of
Figure 3. A heterogeneous metabolic risk proﬁle within the control group. (A) Principal component analysis score plot colored by group: reference group subjects
with nometabolic risk factors (green), subjects with risk factors for MetS but no central obesity (gray), subjects with central obesity and up to 1 other MetS risk factor
(purple), and subjects with deﬁned MetS (orange). The ellipses cover 68% of the subjects belonging to a given subgroup. Loadings for the included parameters are
shown with arrows. ALAT = alanine-aminotransferase, ASAT = aspartate-aminotransferase, C/P ratio = central/peripheral fat mass ratio, cholesterol = total
cholesterol, glucose = fasting glucose, WBC = white blood cell count. Exercise: physical activity. (B) Distribution of the principal component 1 scores for the 4
subgroups. Boxes represent the upper quartile, the mean, and the lower quartile of the data. Whiskers designate the Tukey interval with outliers shown as staggered
dots.
∗∗∗
P<0.001. MetS = metabolic syndrome, non-CO = non-central obese.
Figure 4. Stratiﬁcation of the heterogeneous control group in identiﬁed intermediate subgroups with increased risk for later T2DM and CVD. (A) Multivariate Cox
regression analysis for the risk of developing T2DM and CVD based on control group stratiﬁcation. Subgroups represent reference group with no risk factors for
MetS, subjects with risk factors for MetS but no central obesity, subjects with central obesity and up to one additional MetS risk factor, and subjects with deﬁned
MetS. Values are adjusted for age, smoking, alcohol consumption, and physical activity. CVD = cardiovascular disease, MetS = metabolic syndrome, non-CO =
non-central obesity, T2DM = type 2 diabetes mellitus. (B) Risk of developing T2DM and CVD for subjects with 1 to 5 risk factors for MetS as compared to the
reference group with no MetS risk factors. 0: n=432; 1: n=1404; 2: n=1083; 3: n=647; 4: n=271; and 5: n=68. Values are adjusted for age, smoking, alcohol,
and physical activity. Data represent hazard ratio with 95% conﬁdence interval.
Dragsbæk et al. Medicine (2016) 95:36 www.md-journal.com
5
CVD. Conversely, high blood pressure was a contributor to the
development of CVD events (HR=1.19 [1.09–1.30]) but did not
contribute to an increased risk of T2DM. Neither HDL
cholesterol nor triglyceride levels contributed to an increased
risk of T2DM and CVD in this cohort of elderly Caucasian
women.
3.2. Subgrouping the control group consisting of subjects
with heterogeneous MetS risk factor proﬁles
Since central obesity alone contributed to increased risk of both
T2DM and CVD, we speculated if the subjects with central
obesity in the control group would take part in reducing the
prediction of future disease prevalence within deﬁned MetS
subjects. To examine this question, we divided the heterogeneous
control group into 3 subgroups: subjects with central obesity, and
up to 1 additional MetS risk factor, but not deﬁned with MetS;
subjects without central obesity, but with other risk factors for
the MetS; and subjects with no MetS risk factors.
To capture the multivariate features of the dataset, we used
PCA to visualize the differences between the MetS group and
the three control subgroups (Fig. 3A). We observed a distinct
separation between subjects with deﬁned MetS (orange) and the
control group comprising subjects with no risk factors for MetS
(green), while the non-MetS subjects with central obesity (purple)
and subjects with other MetS risk factors (gray) cut in between
the non-MetS risk factor controls and MetS subjects in the PCA
score plot. Based on the group distributions, the multivariate
analysis indicated that subjects with central obesity and up to 1
MetS risk factor are metabolically more similar to MetS subjects,
while subjects with other MetS risk factors than central obesity
are more similar to the reference group with noMetS risk factors.
The 4 subgroups were found to statistically separate in PC1
(Fig. 3B), meaning that all subgroups differed in the parameters
pulling in the PC1 direction within the loading plot. The
parameters driving this separation are mainly MetS classiﬁcation
parameters such as C/P ratio, BMI, fasting glucose, HDL
cholesterol, triglycerides, and blood pressure. Smoking, LDL
cholesterol, and ASAT had no inﬂuence on the separation of the
subjects in PC1.
Since the PCA indicated that the three subgroups from the
former control group showed differentiated metabolic proﬁles,
we used Cox regression analysis to investigate whether these
subjects also showed different risk proﬁles for T2DM and CVD.
We found that controls with central obesity without MetS had a
2.2-fold increased risk of T2DM (HR=2.21 [1.25–3.93]) and
a 1.5-fold increased risk of CVD (HR=1.51 [1.25–1.83])
compared to the reference group with no risk factors for
MetS (Fig. 4A). Likewise, controls with other MetS risk factors
than central obesity had a 1.8-fold increased risk of T2DM
(HR=1.75 [1.04–2.96]) and a 1.4-fold increased risk of CVD
(HR=1.36 [1.15–1.60]). Moreover, the stratiﬁcation of the
former control group also affected the disease risk in MetS
subjects, as subjects with deﬁned MetS showed a 6.3-fold
increased risk of developing T2DM (HR=6.29 [3.74–10.50])
and a 1.7-fold increased risk of a CVD event (HR=1.72
[1.44–2.05]), when speciﬁcally compared to the reference group
without MetS risk factors.
Further, we explored the effect of the risk factor distribution
further by analyzing the relationship between the cumulated sum
of risk factors and subsequent disease events. The average
number of MetS risk factors for all subjects in the analytical
sample was 1.8±1.2. T2DM risk was increased for subjects with
≥2 MetS risk factors compared to subjects with no risk factors;
1 risk factor: HR=1.20 (0.69–2.09), 2 risk factors: HR=2.44
(1.43–4.17), 3 risk factors: HR=4.70 (2.77–7.98), 4 risk factors:
HR=7.27 (4.19–12.61), and 5 risk factors: HR=11.57
(6.12–21.88), respectively (Fig. 4B). An increased risk of a
CVD event was found with ≥1 risk factor for MetS: HR=1.33
(1.12–1.58), HR=1.47 (1.24–1.75), HR=1.55 (1.29–1.86),
HR=1.75 (1.41–2.18), and HR=2.52 (1.83–3.46), respectively,
as illustrated in Fig. 4B. The incidence rates shown in Table 2
further manifested the differentiated risk within the metabolic
subgroups when stratiﬁed either based on metabolic deﬁnitions
or based on number of risk factors. The lowest incidence was
found in the control group holding no risk factors for MetS, with
an incidence of 2.8 (1.7–4.6) per 1000 person-years for T2DM
and an incidence of 36.3 (31.2–42.2) per 1000 person-years for
CVD. The highest incidence was found in the group holding
5 risk factors for MetS, with an incidence of 36.2 (24.3–54.1) per
1000 person-years for T2DM and an incidence of 96.1
(72.8–126.8) per 1000 person-years for CVD.
4. Discussion
Elderly women with MetS proved to have an increased risk of
developing T2DM and CVD when compared to women not
deﬁned with the syndrome. The increased risk of 3.6-fold for
T2DM and 1.3-fold for CVD found in this study correlated well
with ﬁndings reported in previous studies using a heterogeneous
control group, although these results mostly originate from
cohorts of middle-aged men and women.[10,17–19] We further
reﬁned these results by highlighting how a control group with
heterogeneousMetS risk proﬁles in women without deﬁnedMetS
can lead to a distortion of the hazard estimations associated with
the MetS. We showed how speciﬁcally comparing subjects with
deﬁned MetS to subjects with no risk factors for MetS increased
the risk estimate of future T2DM from 3.6 to 6.3-fold and the risk
of a future CVD event from 1.3 to 1.7-fold. This clearly suggests
that the risk of developing T2DM and CVD in women with
deﬁned MetS is much greater than previously proposed and
further, that the risk of T2DM and CVD also was greater in
women not deﬁned with the syndrome but still holding some risk
factors for MetS. To our knowledge, this type of risk assessment
of the MetS has not previously been reported. In addition, the
analysis of cumulating MetS risk factors showed increasing
risk of later disease with increasing number of risk factors; with
5 MetS risk factors resulting in 11.6-fold increased the risk of
T2DM development and 2.5-fold risk of CVD. This underlines
the value of identifying subjects with MetS risk factors in the
elderly population as well.
Central obesity was the only MetS risk factor that indepen-
dently contributed to the risk of both future T2DM and CVD
(2- and 1.5-fold, respectively). As central obesity is consistently
highlighted as a key contributor to risk in any deﬁnition of the
MetS,[16] our ﬁnding is congruent with this prominent role of
central obesity in the MetS deﬁnition. By partitioning the control
group of non-MetS subjects into 3 subgroups, we repeated our
ﬁnding of a 2-fold increased risk of T2DM and 1.5-fold for
CVD outcomes in subjects with central obesity without MetS.
Furthermore, the PCA revealed that subjects with central obesity
displayed a higher degree of similarity toMetS subjects than the 2
other subgroups without this risk factor, emphasizing the role of
central obesity as a key driver of both T2DMandCVD.While we
clearly demonstrated the predictive value of the MetS in relation
to later risk of T2DM and CVD in elderly Caucasian women,
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we also showed that women not fulﬁlling the full MetS criteria
likewise have a higher risk of developing T2DMandCVD later in
life, if they have one or more of the MetS risk factors at baseline.
This was further illustrated in the differentiated incidence rates
found within the subdivided reference group. Further, the
calculated incidence rates also underlined how the incidence of
both T2DM and CVD increased with increasing numbers of risk
factors.
The prognostic importance of the MetS compared to the
prognostic capability of the sum of the individual MetS risk
factors has previously been challenged by others.[21–23] With the
PCA and risk estimates presented in this study, we add to this
debate by assessing the risk of the individual components,
highlighting the heterogeneity in the metabolic proﬁles of subjects
not deﬁned with MetS, and determining the predictive ability of
the cumulating sum of risk factors constituting the MetS. Other
studies have compared the predictive ability for CVD using both
theMetS deﬁnition and the FraminghamRisk Score[24–26] ﬁnding
similar results for the two scoring systems, and further found the
Diabetes Prediction Model to be superior to the MetS deﬁnition
in predicting the risk of diabetes development.[25] Similarly, the
ﬁndings in our study indicated that deﬁning the MetS does not
supersede the risk estimated when summing the risk of the
individual risk factors. Consequently, our ﬁndings add to the
questioning of applying a MetS deﬁnition to commonly
cooccurring risk factors will provide auxiliary value in the
general practice. Thus, it might be more practical to focus on
developing a classiﬁcation scheme that reﬂects both the degree
and sum of risk factor abnormalities instead of using the current
MetS deﬁnition. This suggestion is founded on the assumption
that cooccurring factors indeed enhance the risk of adverse
outcomes, as was also the result of our current cumulating risk
factor analysis.
Regardless of focusing on MetS as a joined deﬁnition or on the
sum of risk factors, it is known that the prevalence of the risk
factors forMetS increases with age, reaching a prevalence of 40%
in people aged >60 years.[2] The initial indicator of a high-risk
metabolic proﬁle is central obesity, and our present study
coherently points to the high priority of this risk factor in the
elderly segment of the population, when focusing on preventing
T2DM and CVD and in advancing efforts to regulate the obesity
epidemic.
The strengths of this study include its longitudinal design,
detailed assessment of metabolic risk factors, and exclusion of
subjects with T2DM and CVD at baseline. The study’s follow-up
information was derived from Danish registry data, which is of
high quality based on the use of a unique personal identiﬁer and
nationwide electronic patient records, and thus results in limited
loss of data from baseline to follow-up. The cohort consists of a
large group of women in Denmark, where the homogenous
population with equal access to primary care (tax-paid, not
individually paid) may limit extrapolations to other populations.
However, the hazard ratios found in this study are comparable to
associations found in similar cohorts, though with different age
distributions, which indicates that such generalizations are
indeed plausible. By applying PCA as a multivariate tool to
assess risk proﬁles, we introduce a possible confounder, as we
subdivide the study population before PCA based on central
obesity. With this common denominator being present in both
the MetS group and the non-MetS group with central obesity, we
potentially skew these 2 subgroups toward each other compared
to the non-MetS group holding other risk factors forMetS, as this
subgroup may be regarded as being more heterogeneous (by not
having obesity as a common denominator). However, based on
the MetS deﬁnition, it is not possible to circumvent this type of
limitation. In this study, central obesity was determined byDEXA
scan rather than waist circumference originally proposed by IDF.
However, IDF does highlight that DEXA scan can be used as an
additional factor in research of theMetS, which can allow further
modiﬁcation of the deﬁnition if necessary.
Elderly Caucasian women fulﬁlling the MetS criteria set by the
IDF showed increased risk of future T2DM or CVD diagnosis;
however, subjects who did not fulﬁll the criteria for MetS but
presented one or more of the components of MetS were also at
increased risk. A further subdivision of the reference group
proved to increase the risk of T2DM to 6.3-fold (from 3.6-fold)
and 1.7-fold for CVD (from 1.3-fold) for MetS subjects when
compared to a reference group only including subjects with no
MetS risk factors. In clinical practice, employment of the MetS in
elderly women should be focused as a tool for identifying subjects
with metabolic high-risk proﬁles. However, the sum of risk
factors are proposed to be equally considered, as subjects not
ﬁtting the MetS-criterion, but still holding one or more risk
factors for MetS, were here identiﬁed also to be at increased risk
of T2DM and CVD.
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